Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
dcw
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Dr. Weisman interviewed on Senior Advocates, Who’s Who
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Dr. Weisman interviewed in Neurology Insights
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
The Pandemic Will End: How and Why
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
Alzheimer’s Patient Newsletter February 2020
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
Dr. Weisman interviewed on Boomer Living podcast
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”
MS Patient Newsletter December 2019
The field of MS research has had amazing success in the last two decades.
MS Physician Newsletter October 2019
Multiple sclerosis (MS) is an autoimmune disease in which the immune system misrecognizes part of the brain called myelin.